Cannabinoids inhibit fibrogenesis in diffuse systemic sclerosis fibroblasts

Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays

Mosmann, T. (1983) · Journal of Immunological Methods · doi:10.1016/0022-1759(83)90303-4 · Cited by 56,104 · see citing works

Molecular characterization of a peripheral receptor for cannabinoids

Munro, S., Thomas, K. L., & Abu-Shaar, M. (1993) · Nature · doi:10.1038/365061a0 · Cited by 5,092 · see citing works

Structure of a cannabinoid receptor and functional expression of the cloned cDNA

Matsuda, L. A., Lolait, S. J., Brownstein, M. J., Young, A. C., & Bonner, T. I. (1990) · Nature · doi:10.1038/346561a0 · Cited by 5,011 · see citing works

Preliminary criteria for the classification of systemic sclerosis (scleroderma)

Masi, A. T. (1980) · Arthritis & Rheumatism · doi:10.1002/art.1780230510 · Cited by 4,925 · see citing works

The Endocannabinoid System as an Emerging Target of Pharmacotherapy

Pacher, P., Bátkai, S., & Kunos, G. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.2 · Cited by 2,077 · see citing works

Cannabinoid-based drugs as anti-inflammatory therapeutics

Klein, T. W. (2005) · Nature Reviews Immunology · doi:10.1038/nri1602 · Cited by 728 · see citing works

GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current

Lauckner, J. E., Jensen, J. B., Chen, H.-Y., Lu, H., Hille, B., & Mackie, K. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711278105 · Cited by 710 · see citing works

Cannabinoid Receptors: Where They are and What They do

Mackie, K. (2008) · Journal of Neuroendocrinology · doi:10.1111/j.1365-2826.2008.01671.x · Cited by 638 · see citing works

Stimulatory Autoantibodies to the PDGF Receptor in Systemic Sclerosis

Svegliati, S., Santillo, M., Bevilacqua, F., Luchetti, M. M., Spadoni, T., Mancini, M., Fraticelli, P., Sambo, P., Funaro, A., Kazlauskas, A., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052955 · Cited by 581 · see citing works

CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis

Teixeira-Clerc, F., Julien, B., Grenard, P., Nhieu, J. T. V., Deveaux, V., Li, L., Serrière-Lanneau, V., Ledent, C. A., Mallat, A., & Lotersztajn, S. (2006) · Nature Medicine · doi:10.1038/nm1421 · Cited by 527 · see citing works

Antifibrogenic role of the cannabinoid receptor CB2 in the liver

Julien, B., Grenard, P., Teixeira-Clerc, F., Nhieu, J. T. V., Li, L., Karsak, M., Zimmer, A., Mallat, A., & Lotersztajn, S. (2005) · Gastroenterology · doi:10.1053/j.gastro.2004.12.050 · Cited by 470 · see citing works

The endocannabinoid system as a target for therapeutic drugs

Piomelli, D., Giuffrida, A., Calignano, A., & Rodrı́guez de Fonseca, F. (2000) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(00)01482-6 · Cited by 421 · see citing works

Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis

Distler, J. H. W., Jüngel, A., Huber, L. C., Schulze‐Horsel, U., Zwerina, J., Gay, R. E., Michel, B. A., Hauser, T., Schett, G., Gay, S., et al. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22314 · Cited by 383 · see citing works

Stimulation of Collagen and Glycosaminoglycan Production in Cultured Human Adult Dermal Fibroblasts by Recombinant Human Interleukin 6

Duncan, M. R., & Berman, B. (1991) · Journal of Investigative Dermatology · doi:10.1111/1523-1747.ep12483971 · Cited by 325 · see citing works

Serum levels of interleukin-6 and interleukin-10 correlate with total skin thickness score in patients with systemic sclerosis

Sato, S., Hasegawa, M., & Takehara, K. (2001) · Journal of Dermatological Science · doi:10.1016/s0923-1811(01)00128-1 · Cited by 298 · see citing works

Dual inhibition of c-abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis

Akhmetshina, A., Dees, C., Pileckyte, M., Maurer, B., Axmann, R., Jüngel, A., Zwerina, J., Gay, S., Schett, G., Distler, O., et al. (2008) · The FASEB Journal · doi:10.1096/fj.07-105627 · Cited by 187 · see citing works

Platelet-derived Growth Factor and Reactive Oxygen Species (ROS) Regulate Ras Protein Levels in Primary Human Fibroblasts via ERK1/2

Svegliati, S., Cancello, R., Sambo, P., Luchetti, M. M., Paroncini, P., Orlandini, G., Discepoli, G., Paternò, R., Santillo, M., Cuozzo, C., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m502851200 · Cited by 173 · see citing works

Anandamide induces necrosis in primary hepatic stellate cells†‡

Siegmund, S., Uchinami, H., Osawa, Y., Brenner, D. A., & Schwabe, R. F. (2005) · Hepatology · doi:10.1002/hep.20667 · Cited by 171 · see citing works

Cannabinoids down-regulate PI3K/Akt and Erk signalling pathways and activate proapoptotic function of Bad protein

Ellert‐Miklaszewska, A., Kamińska, B., & Konarska, L. (2004) · Cellular Signalling · doi:10.1016/j.cellsig.2004.05.011 · Cited by 167 · see citing works

New developments in fibroblast and myofibroblast biology: Implications for fibrosis and scleroderma

Abraham, D., Eckes, B., Rajkumar, V. S., & Krieg, T. M. (2007) · Current Rheumatology Reports · doi:10.1007/s11926-007-0008-z · Cited by 163 · see citing works

The cannabinoid WIN 55,212-2 inhibits transient receptor potential vanilloid 1 (TRPV1) and evokes peripheral antihyperalgesia via calcineurin

Patwardhan, A. M., Jeske, N. A., Price, T. J., Gamper, N. L., Akopian, A. N., & Hargreaves, K. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0603861103 · Cited by 161 · see citing works

Matrix Contraction by Dermal Fibroblasts Requires Transforming Growth Factor-β/Activin-Linked Kinase 5, Heparan Sulfate-Containing Proteoglycans, and MEK/ERK

Chen, Y., Shiwen, X., Beek, J. V., Kennedy, L., McLeod, M. R., Renzoni, E. A., Bou–Gharios, G., Wilcox‐Adelman, S. A., Goetinck, P. F., Eastwood, M., et al. (2005) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)61252-7 · Cited by 135 · see citing works

Adenosine A 2A receptors in diffuse dermal fibrosis: Pathogenic role in human dermal fibroblasts and in a murine model of scleroderma

Chan, E. S. L., Fernandez, P., Merchant, A., Montesinos, M. C., Trzaska, S., Desai, A., Tung, C., Khoa, D. N. Y., Pillinger, M. H., Reiss, A. B., et al. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21974 · Cited by 134 · see citing works

IL-6 Modulates Alpha-Smooth Muscle Actin Expression in Dermal Fibroblasts from IL-6-Deficient Mice

Gallucci, R. M., Lee, E. G., & Tomasek, J. J. (2006) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5700109 · Cited by 134 · see citing works

The cannabinoid receptor CB2 exerts antifibrotic effects in experimental dermal fibrosis

Akhmetshina, A., Dees, C., Busch, N., Beer, J., Sarter, K., Zwerina, J., Zimmer, A., Distler, O., Schett, G. A., & Distler, J. H. W. (2009) · Arthritis & Rheumatism · doi:10.1002/art.24395 · Cited by 126 · see citing works

The endocannabinoid 2‐arachidonoyl glycerol induces death of hepatic stellate cells via mitochondrial reactive oxygen species

Siegmund, S., Qian, T., Minicis, S. D., Harvey-White, J. D., Kunos, G., Vinod, K. Y., Hungund, B. L., & Schwabe, R. F. (2007) · The FASEB Journal · doi:10.1096/fj.06-7717com · Cited by 124 · see citing works

Cannabinoids: A New Group of Agonists of PPARs

Sun, Y., & Bennett, A. (2007) · PPAR Research · doi:10.1155/2007/23513 · Cited by 109 · see citing works

Opposing Effects of Protein Kinase Cα and Protein Kinase Cϵ on Collagen Expression by Human Lung Fibroblasts Are Mediated via MEK/ERK and Caveolin-1 Signaling

Tourkina, E., Göőz, P., Pannu, J., Bonner, M., Scholz, D., Hacker, S., Silver, R. M., Trojanowska, M. E., & Hoffman, S. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m412551200 · Cited by 103 · see citing works

Species comparison and pharmacological characterization of rat and human CB2 cannabinoid receptors

Mukherjee, S., Adams, M., Whiteaker, K. L., Daza, A. V., Kage, K., Cassar, S. C., Meyer, M., & Yao, B. B. (2004) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2004.09.058 · Cited by 99 · see citing works

Receptor-Independent Effects of Endocannabinoids on Ion Channels

Oz, M. (2005) · Current Pharmaceutical Design · doi:10.2174/138161206775193073 · Cited by 71 · see citing works

Transcriptional profiling of the scleroderma fibroblast reveals a potential role for connective tissue growth factor (CTGF) in pathological fibrosis

Leask, A. (2004) · The Keio Journal of Medicine · doi:10.2302/kjm.53.74 · Cited by 60 · see citing works

Prospects for cannabinoids as anti‐inflammatory agents

Zurier, R. B. (2002) · Journal of Cellular Biochemistry · doi:10.1002/jcb.10291 · Cited by 57 · see citing works

Inhibitory effect of synthetic cannabinoids on cytokine production in rheumatoid fibroblast-like synoviocytes.

Selvi, E., Lorenzini, S., Garcia-Gonzalez, E., Maggio, R., Lazzerini, P. E., Capecchi, P. L., Balistreri, E., Spreafico, A., Niccolini, S., Pompella, G., et al. (2008) · PubMed · Cited by 54 · see citing works

Cannabinoids Reduce Markers of Inflammation and Fibrosis in Pancreatic Stellate Cells

Michalski, C. W., Maier, M., Erkan, M., Sauliunaite, D., Bergmann, F., Pacher, P., Bátkai, S., Giese, N. A., Giese, T., Frieß, H., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0001701 · Cited by 54 · see citing works

Growth state-dependent regulation of plasminogen activator inhibitor type-1 gene expression during epithelial cell stimulation by serum and transforming growth factor-?1

Boehm, J. R., Kutz, S. M., Sage, E. H., Staiano‐Coico, L., & Higgins, P. J. (1999) · Journal of Cellular Physiology · doi:10.1002/(sici)1097-4652(199910)181:1 · Cited by 32 · see citing works

The IL - 6 promoter polymorphism is associated with disease activity and disability in systemic sclerosis

Sfrent‐Cornateanu, R., Mihai, C., Balan, S., Ionescu, R. M., & Moldoveanu, E. (2006) · Journal of Cellular and Molecular Medicine · doi:10.2755/jcmm010.004.08 · Cited by 27 · see citing works

The IL - 6 promoter polymorphism is associated with disease activity and disability in systemic sclerosis

Sfrent‐Cornateanu, R., Mihai, C., Balan, S., Ionescu, R. M., & Moldoveanu, E. (2006) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2006.tb00538.x · Cited by 23 · see citing works

Serological assessment of type I collagen burden in scleroderma spectrum disorders: a systematic review.

Dziadzio, M., Smith, R. E., Abraham, D., Stratton, R. J., Gabrielli, A., Black, C. M., & Denton, C. P. (2004) · PubMed · Cited by 15 · see citing works

The influence of volume loading on the inotropic effect of Ro 7-2956

Osborne, M. W., Wenger, J. J., Zanko, M. T., & Barrett, R. J. (1974) · European Journal of Pharmacology · doi:10.1016/0014-2999(74)90105-8 · Cited by 9 · see citing works

Pathogenesis of Systemic Sclerosis

Pattanaik, D., Brown, M. A., Postlethwaite, B. C., & Postlethwaite, A. E. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00272 · Cited by 423 · see citing works

Cannabinoid Signaling in the Skin: Therapeutic Potential of the “C(ut)annabinoid” System

Tóth, K. F., Ádám, D., Bı́ró, T., & Oláh, A. (2019) · Molecules · doi:10.3390/molecules24050918 · Cited by 209 · see citing works

Systemic sclerosis – multidisciplinary disease: clinical features and treatment

Sobolewski, P., Maślińska, M., Wieczorek, M., Łagun, Z., Malewska, A., Roszkiewicz, M., Nitskovich, R., Szymańska, E., & Walecka, I. (2019) · Reumatologia/Rheumatology · doi:10.5114/reum.2019.87619 · Cited by 170 · see citing works

Unraveling SSc Pathophysiology; The Myofibroblast

van Caam, A., Vonk, M., van den Hoogen, F., van Lent, P., & van der Kraan, P. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02452 · Cited by 153 · see citing works

The endocannabinoid system of the skin. A potential approach for the treatment of skin disorders

del Río, C., Millán, E., García, V., Appendino, G., DeMesa, J., & Muñóz, E. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.08.022 · Cited by 119 · see citing works

Safety and Efficacy of Lenabasum in a Phase II, Randomized, Placebo‐Controlled Trial in Adults With Systemic Sclerosis

Spiera, R., Hummers, L. K., Chung, L. S., Frech, T., Domsic, R. T., Hsu, V. M., Furst, D. E., Gordon, J., Mayes, M. D., Simms, R. W., et al. (2020) · Arthritis & Rheumatology · doi:10.1002/art.41294 · Cited by 106 · see citing works

Cannabinoids in the Pathophysiology of Skin Inflammation

Scheau, C., Bădărău, I. A., Mihai, L.-G., Scheau, A.-E., Costache, D. O., Constantin, C., Călina, D. C., Căruntu, C., Costache, R. S., & Căruntu, A. (2020) · Molecules · doi:10.3390/molecules25030652 · Cited by 98 · see citing works

Synthetic cannabinoid ajulemic acid exerts potent antifibrotic effects in experimental models of systemic sclerosis

González, E. G., Selvi, E., Balistreri, E., Akhmetshina, A., Palumbo, K., Lorenzini, S., Lazzerini, P. E., Montilli, C., Capecchi, P. L., Lucattelli, M., et al. (2012) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2011-200314 · Cited by 95 · see citing works

Antiproliferative Effects of Cannabinoid Agonists on Deep Infiltrating Endometriosis

Leconte, M., Nicco, C., Ngô, C., Arkwright, S., Chéreau, C., Guibourdenche, J., Weill, B. J., Chapron, C., Dousset, B. E., & Batteux, F. (2010) · American Journal Of Pathology · doi:10.2353/ajpath.2010.100375 · Cited by 85 · see citing works

Cannabinoids in dermatology: a scoping review

Eagleston, L. R. M., Kalani, N., Patel, R. R., Flaten, H. K., Dunnick, C. A., & Dellavalle, R. P. (2018) · Dermatology Online Journal · doi:10.5070/d3246040706 · Cited by 85 · see citing works

Inactivation of the cannabinoid receptor CB1 prevents leukocyte infiltration and experimental fibrosis

Marquart, S., Zerr, P., Akhmetshina, A., Palumbo, K., Reich, N., Tomčík, M., Horn, A., Dees, C., Engel, M., Zwerina, J., et al. (2010) · Arthritis & Rheumatism · doi:10.1002/art.27642 · Cited by 78 · see citing works

Safety and efficacy of lenabasum in a phase 2 randomized, placebo-controlled trial in adults with cystic fibrosis

Chmiel, J. F., Flume, P. A., Downey, D. G., Dozor, A. J., Colombo, C., Mazurek, H., Sapiejka, E., Rachel, M., Constantine, S., Conley, B., et al. (2020) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2020.09.008 · Cited by 71 · see citing works

Cannabinoids for the treatment of rheumatic diseases — where do we stand?

Katz, D., Katz, I., Porat-Katz, B.-S., & Shoenfeld, Y. (2018) · Nature Reviews Rheumatology · doi:10.1038/s41584-018-0025-5 · Cited by 66 · see citing works

New trends for the medical treatment of endometriosis

Rocha, A. L. L., Reis, F. M., & Petraglia, F. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.683783 · Cited by 60 · see citing works

Bi-directional communication: Conversations between fibroblasts and immune cells in systemic sclerosis

Worrell, J. C., & O’Reilly, S. (2020) · Journal of Autoimmunity · doi:10.1016/j.jaut.2020.102526 · Cited by 59 · see citing works

The cannabinoid WIN55, 212-2 abrogates dermal fibrosis in scleroderma bleomycin model

Balistreri, E., Garcia-Gonzalez, E., Selvi, E., Akhmetshina, A., Palumbo, K., Lorenzini, S., Maggio, R., Lucattelli, M., Galeazzi, M., & Distler, J. W. H. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.137539 · Cited by 56 · see citing works

Adenosine A2A receptor activation stimulates collagen production in sclerodermic dermal fibroblasts either directly and through a cross-talk with the cannabinoid system

Lazzerini, P. E., Natale, M., Gianchecchi, E., Capecchi, P. L., Montilli, C., Zimbone, S., Castrichini, M., Balistreri, E., Ricci, G., Selvi, E., et al. (2011) · Journal of Molecular Medicine · doi:10.1007/s00109-011-0824-5 · Cited by 54 · see citing works

Expression of the endocannabinoid receptors in human fascial tissue

Fede, C., Albertin, G., Petrelli, L., Sfriso, M. M., Biz, C., De, R., & Stecco, C. (2016) · European Journal of Histochemistry · doi:10.4081/ejh.2016.2643 · Cited by 53 · see citing works

Relevance of Peroxisome Proliferator Activated Receptors in Multitarget Paradigm Associated with the Endocannabinoid System

Lago-Fernandez, A., Zarzo-Arias, S., Jagerovic, N., & Morales, P. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22031001 · Cited by 47 · see citing works

Cannabinoids: Potential Role in Inflammatory and Neoplastic Skin Diseases

Milando, R., & Friedman, A. (2018) · American Journal of Clinical Dermatology · doi:10.1007/s40257-018-0410-5 · Cited by 48 · see citing works

Current and Potential New Targets in Systemic Sclerosis Therapy: a New Hope

Hinchcliff, M., & O’Reilly, S. (2020) · Current Rheumatology Reports · doi:10.1007/s11926-020-00918-3 · Cited by 41 · see citing works

Medical cannabis: Another piece in the mosaic of autoimmunity?

Katz, D. H., Katz, I., Porat‐Katz, B., & Shoenfeld, Y. (2016) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.568 · Cited by 41 · see citing works

Therapeutic Approaches to Systemic Sclerosis: Recent Approvals and Future Candidate Therapies

Lescoat, A., Roofeh, D., Kuwana, M., Lafyatis, R., Allanore, Y., & Khanna, D. (2021) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-021-08891-0 · Cited by 41 · see citing works

VCE ‐004.3, a cannabidiol aminoquinone derivative, prevents bleomycin‐induced skin fibrosis and inflammation through PPARγ‐ and CB 2 receptor‐dependent pathways

del Río, C., Cantarero, I., Palomares, B., Gómez‐Cañas, M., Fernández‐Ruíz, J., Pavicic, C., García‐Martín, A., Bellido, M. L., Castro, R. O., Pérez‐Sánchez, C., et al. (2018) · British Journal of Pharmacology · doi:10.1111/bph.14450 · Cited by 38 · see citing works

Celastrol is a novel selective agonist of cannabinoid receptor 2 with anti-inflammatory and anti-fibrotic activity in a mouse model of systemic sclerosis

Jiang, X., Chen, S., Zhang, Q., Yi, C., He, J., Ye, X., Liu, M., & Lü, W. (2019) · Phytomedicine · doi:10.1016/j.phymed.2019.153160 · Cited by 36 · see citing works

EHP-101, an oral formulation of the cannabidiol aminoquinone VCE-004.8, alleviates bleomycin-induced skin and lung fibrosis

García‐Martín, A., Garrido‐Rodríguez, M., Navarrete, C. M., del Río, C., Bellido, M. L., Appendino, G., Calzado, M. A., & Muñóz, E. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.07.047 · Cited by 34 · see citing works

Medical cannabis and cannabinoids in rheumatology: where are we now?

Sarzi‐Puttini, P., Batticciotto, A., Atzeni, F., Bazzichi, L. M., Franco, M. D., Salaffi, F., Marotto, D., Ceribelli, A., Ablin, J. N., & Häuser, W. (2019) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2019.1665997 · Cited by 33 · see citing works

New Insights into Profibrotic Myofibroblast Formation in Systemic Sclerosis: When the Vascular Wall Becomes the Enemy

Romano, E., Rosa, I., Fioretto, B. S., Matucci‐Cerinic, M., & Manetti, M. (2021) · Life · doi:10.3390/life11070610 · Cited by 34 · see citing works

Inactivation of fatty acid amide hydrolase exacerbates experimental fibrosis by enhanced endocannabinoid-mediated activation of CB1

Palumbo‐Zerr, K., Horn, A., Distler, A., Zerr, P., Dees, C., Beyer, C., Selvi, E., Cravatt, B. F., Distler, O., Schett, G. A., et al. (2012) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-201823 · Cited by 33 · see citing works

Pulmonary microvascular endothelial cells from bleomycin‐induced rats promote the transformation and collagen synthesis of fibroblasts

Yin, Q., Nan, H., Zhang, W., Yan, L., Cui, G., Huang, X., & Wei, J.-G. (2010) · Journal of Cellular Physiology · doi:10.1002/jcp.22545 · Cited by 27 · see citing works

Cutaneous endocannabinoid system: Does it have a role on skin wound healing bearing fibrosis?

Correia‐Sá, I., Paiva, A., Carvalho, C., & Vieira‐Coelho, M. A. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104862 · Cited by 27 · see citing works

Peripherally Restricted Cannabinoids for the Treatment of Pain

Romero-Sandoval, E. A., Asbill, S., Paige, C. A., & Byrd-Glover, K. (2015) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1642 · Cited by 26 · see citing works

The Potential Use of Cannabis in Tissue Fibrosis

Pryimak, N., Zaiachuk, M., Kovalchuk, O., & Kovalchuk, I. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.715380 · Cited by 23 · see citing works

Cannabinoid Compounds as a Pharmacotherapeutic Option for the Treatment of Non-Cancer Skin Diseases

Ramer, R., & Hinz, B. (2022) · Cells · doi:10.3390/cells11244102 · Cited by 24 · see citing works

Mechanisms of Cannabinoids and Potential Applicability to Skin Diseases

Cintosun, A., Lara‐Corrales, I., & Pope, E. (2020) · Clinical Drug Investigation · doi:10.1007/s40261-020-00894-7 · Cited by 24 · see citing works

The Role of Pro-fibrotic Myofibroblasts in Systemic Sclerosis: From Origin to Therapeutic Targeting

Romano, E., Rosa, I., Fioretto, B. S., Matucci‐Cerinic, M., & Manetti, M. (2021) · Current Molecular Medicine · doi:10.2174/0929867328666210325102749 · Cited by 23 · see citing works

Therapeutic Attributes of Endocannabinoid System against Neuro-Inflammatory Autoimmune Disorders

Ahmed, I., Rehman, S. U., Shahmohamadnejad, S., Zia, M. A., Ahmad, M. M., Saeed, M. M., Akram, Z., Iqbal, H. M. N., & Liu, Q. (2021) · Molecules · doi:10.3390/molecules26113389 · Cited by 20 · see citing works

Signaling through the type 2 cannabinoid receptor regulates the severity of acute and chronic graft-versus-host disease

Yuan, C., Zhou, V., Sauber, G., Stollenwerk, T. M., KOMOROWSKI, R. A., López, A., Tolón, R. M., Romero, J., Hillard, C. J., & Drobyski, W. R. (2020) · Blood · doi:10.1182/blood.2020004871 · Cited by 19 · see citing works

AM251, a cannabinoid receptor 1 antagonist, prevents human fibroblasts differentiation and collagen deposition induced by TGF-β – An in vitro study

Correia‐Sá, I., Carvalho, C., Serrão, P., Machado, V., Carvalho, S., Marques, M., & Vieira‐Coelho, M. A. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173738 · Cited by 18 · see citing works

Targeting cannabinoid receptor 2 (CB2) limits collagen production—An in vitro study in a primary culture of human fibroblasts

Correia‐Sá, I., Carvalho, C., Machado, V., Carvalho, S., Serrão, P., Marques, M., & Vieira‐Coelho, M. A. (2021) · Fundamental and Clinical Pharmacology · doi:10.1111/fcp.12716 · Cited by 18 · see citing works

ACPA Alleviates Bleomycin-Induced Pulmonary Fibrosis by Inhibiting TGF-β-Smad2/3 Signaling-Mediated Lung Fibroblast Activation

Chen, D., Tang, H., Jiang, H., Sun, L., Zhao, W., & Qian, F. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.835979 · Cited by 14 · see citing works

Cannabinoids in rheumatology: Friend, foe or a bystander?

Jain, N., & Moorthy, A. (2022) · Musculoskeletal Care · doi:10.1002/msc.1636 · Cited by 15 · see citing works

Cannabinoid receptor 2 selective agonist alleviates systemic sclerosis by inhibiting Th2 differentiation through JAK/SOCS3 signaling

Tian, N., Cheng, H., Du, Y. L., Wang, X., Yi, L., Liu, X., Chen, M., Xu, Z., Wang, L., Yin, H., et al. (2024) · Journal of Autoimmunity · doi:10.1016/j.jaut.2024.103233 · Cited by 14 · see citing works

Therapeutic potential of agents targeting cannabinoid type 2 receptors in organ fibrosis

Eddin, L. B., Meeran, M. F. N., Subramanya, S. B., Jha, N. K., & Ojha, S. K. (2024) · Pharmacology Research & Perspectives · doi:10.1002/prp2.1219 · Cited by 11 · see citing works

Myofibroblasts and their resistance to apoptosis: a possible mechanism of osteoradionecrosis

Tian, L. (2012) · Clinical Cosmetic and Investigational Dentistry · doi:10.2147/ccide.s33722 · Cited by 8 · see citing works

β-Caryophyllene Ameliorates Thioacetamide-Induced Liver Fibrosis in Rats: A Preventative Approach

Eddin, L. B., Mahgoub, A., Almarzooqi, S. S., Adeghate, E. A., Subramanya, S. B., & Ojha, S. K. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26178493 · Cited by 7 · see citing works

Cannabinoids in Autoimmune and Rheumatic Diseases

Navarini, L., Margiotta, D. P. E., Afflitto, G. G., & Afeltra, A. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814307-0.00038-4 · Cited by 7 · see citing works

Antifibrotics in systemic sclerosis

Martín-López, M., & Carreira, P. E. (2021) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2021.101671 · Cited by 7 · see citing works

Emerging therapeutics in the management of connective tissue disease. Part II: Dermatomyositis and scleroderma

Kodumudi, V., Bibb, L. A., Aðalsteinsson, J. A., Shahriari, N., Skudalski, L., Santiago, S., Grant-Kels, J. M., & Lu, J. (2022) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2021.12.068 · Cited by 6 · see citing works

The role of antifibrotic therapies in the treatment of systemic sclerosis–associated interstitial lung disease

Boleto, G., Avouac, J., & Allanore, Y. (2022) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x211066686 · Cited by 6 · see citing works

Drug development and novel therapeutics to ensure a personalized approach in the treatment of systemic sclerosis

Farina, N., Campochiaro, C., Lescoat, A., Benanti, G., Luca, G. D. D., Khanna, D., Dagna, L., & Matucci‐Cerinic, M. (2023) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2023.2230370 · Cited by 5 · see citing works

Current immunosuppressive and antifibrotic therapies of systemic sclerosis and emerging therapeutic strategies

Fallet, B., & Walker, U. A. (2020) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2020.1832466 · Cited by 5 · see citing works

Myofibroblasts and their resistance to apoptosis: a possible mechanism of osteoradionecrosis

Tian, L. (2012) · Clinical Cosmetic and Investigational Dentistry · doi:10.2147/cciden.s33722 · Cited by 5 · see citing works

Antifibrotic therapeutic strategies in systemic sclerosis: Critical role of the Wnt/β-catenin and TGF-β signal transduction pathways as potential targets

Bagheri, L., Javanbakht, M., Malekian, S., Ghahderijani, B. H., Taghipour, S., Tanha, F. D., Ranjkesh, M. H., Cegolon, L., & Zhao, S. G. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177607 · Cited by 4 · see citing works

Where have the organizers gone? – The growth control system as a foundation of physiology

Li, Z., & Shang, C. (2016) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2016.09.001 · Cited by 2 · see citing works

Physiopathology and use of cannabinoids for fibrotic diseases

del Río, C., & Muñóz, E. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-90036-2.00034-x · Cited by 1 · see citing works

Applications to wound healing: Cannabinoid receptor 1 antagonism and collagen deposition

Correia‐Sá, I. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-90877-1.00017-6 · Cited by 1 · see citing works

Simulated annealing model of acupuncture

Shang, C., & Szu, H. H. (2015) · Proceedings of SPIE, the International Society for Optical Engineering/Proceedings of SPIE · doi:10.1117/12.2185052 · Cited by 1 · see citing works

Symposium Summaries

(2017) · Pediatric Pulmonology · doi:10.1002/ppul.23839 · Cited by 1 · see citing works

Vasoactive and Antifibrotic Properties of Cannabinoids and Applications to Vasospastic/Vaso-Occlusive Disorders

Li, G., Choi, J., Stephens, K. L., & DeGeorge, B. R. (2024) · Annals of Plastic Surgery · doi:10.1097/sap.0000000000003985 · Cited by 1 · see citing works

Brief Report of the Therapeutic Potential of Utilizing the Cannabinoid Receptor in Systemic Sclerosis (SSc)

Spigarelli, T. M. F. M. G. (2015) · Rheumatology Current Research · doi:10.4172/2161-1149.s6-004

Cannabinoids and retinal fibrotic disorders.

Sloan, L. J. (2022) · doi:10.18297/etd/3869

Topografische Anatomie

Schleip, R., & Huijing, P. A. (2026) · Elsevier eBooks · doi:10.1016/b978-3-437-55038-6.00001-4

Cannabinoids inhibit fibrogenesis in diffuse systemic sclerosis fibroblasts. Rheumatology (Oxford

Garcia-Gonzalez, E., Selvi, E., Balistreri, E., Lorenzini, S., Maggio, R., Natale, M., Capecchi, P.-L., Lazzerini, P.-E., Bardelli, M., Pasini, F. L., et al. (2016)

The cannabinoid WIN55, 212-2 abrogates dermal fibrosis in scleroderma bleomycin model

Balistreri, E., Garcia-Gonzalez, E., Selvi, E., Akhmetshina, A., Palumbo, K., Lorenzini, S., Maggio, R., Lucattelli, M., Galeazzi, M., & Distler, J. W. H. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.137539 · Cited by 56 · see citing works

Targeting the Cannabinoid Pathway Limits the Development of Fibrosis and Autoimmunity in a Mouse Model of Systemic Sclerosis

Servettaz, A., Kavian, N., Nicco, C., Deveaux, V., Chéreau, C., Wang, A., Zimmer, A., Lotersztajn, S., Weill, B. J., & Batteux, F. (2010) · American Journal Of Pathology · doi:10.2353/ajpath.2010.090763 · Cited by 119 · see citing works

Adenosine A2A receptor activation stimulates collagen production in sclerodermic dermal fibroblasts either directly and through a cross-talk with the cannabinoid system

Lazzerini, P. E., Natale, M., Gianchecchi, E., Capecchi, P. L., Montilli, C., Zimbone, S., Castrichini, M., Balistreri, E., Ricci, G., Selvi, E., et al. (2011) · Journal of Molecular Medicine · doi:10.1007/s00109-011-0824-5 · Cited by 54 · see citing works

Cannabinoid receptors in SSc

Buckland, J. (2009) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2009.95